⌕
GRAIL · GRAL · Nasdaq
Tenet 61 · Solid
Compare
$105.60−8.88%At closeTenet 61 · Solid
$105.60−10.29 (−8.88%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

GRAIL (GRAL) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● Fool - Investing NewsNov 10, 2026 · 16:30 ET
Got $10,000? 3 Hot Stocks to Buy That Could Make You a Fortune

Grail, Agility Robotics, and Sandisk could deliver multibagger gains in the future.…

● Seeking AlphaNov 10, 2026 · 13:31 ET
GRAIL, Inc. (GRAL) Presents at 2026 UBS Global Healthcare Conference Transcript

GRAIL, Inc. ( GRAL ) 2026 UBS Global Healthcare Conference November 10, 2026 11:00 AM EST Company Participants Aaron Freidin - CFO & Head of Corporate Development Conference Call Participants Douglas Schenkel - UBS Inves…

● Zacks Investment ResearchNov 5, 2026 · 11:01 ETEARNINGS EXPECTED BY FEB 19
GRAIL Q3 Earnings Call Ties FDA Review to Pricing and Sales Growth

GRAL is cutting Galleri prices to boost adoption ahead of an expected early 2027 FDA decision, even as pricing pressure weighs on revenue growth and margins.…

● Seeking AlphaNov 4, 2026 · 21:24 ETEARNINGS EXPECTED BY FEB 19
GRAIL, Inc. (GRAL) Q3 2026 Earnings Call Transcript

GRAIL, Inc. (GRAL) Q3 2026 Earnings Call Transcript…

● MarketBeatNov 4, 2026 · 20:14 ETEARNINGS EXPECTED BY FEB 19
What GRAIL (GRAL) Said on Its Q3 Earnings Call

GRAIL NASDAQ: GRAL reported 4% revenue growth for the third quarter of 2026 as higher testing volumes were offset in part by lower prices, and said it expects a U.S. regulatory decision on its Galleri cancer screening te…

● PRNewsWireNov 4, 2026 · 16:02 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 19
GRAIL Reports Third Quarter 2026 Financial Results

FDA Advisory Committee Voted in Favor of Approval of GRAIL's Galleri Multi-Cancer Early Detection Test Q3 Galleri ® Test Volume Increased ~24% to More Than 56,000 Year-Over-Year, Year-to-Date Test Volume Increased ~36% t…

● Zacks Investment ResearchOct 29, 2026 · 13:11 ETEARNINGS EXPECTED BY FEB 19
GRAIL Q3 Earnings Ahead: Galleri Test Adoption to Drive Growth

GRAL's Q3 earnings should have benefited from rising Galleri test adoption, expanding digital health partnerships and growing clinical evidence of cancer detection.…

● PRNewsWireOct 27, 2026 · 16:02 ETCOMPANY'S OWN WORDS
GRAIL to Present at the UBS Global Healthcare Conference

SUNNYVALE, Calif., Oct. 27, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the …

● PRNewsWireOct 21, 2026 · 16:02 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 19
GRAIL to Announce Third Quarter 2026 Financial Results

SUNNYVALE, Calif., Oct. 21, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the…

● Defense WorldOct 18, 2026 · 04:09 ET
GRAIL (NASDAQ:GRAL) Stock: Insider Joshua Ofman Sells 20,000 Shares

GRAIL, Inc. (NASDAQ: GRAL - Get Free Report) CEO Joshua Ofman sold 20,000 shares of the firm's stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $136.85, for a total value o…

● Defense WorldOct 18, 2026 · 02:21 ET
GRAIL (NASDAQ:GRAL) Stock Price Down 5.6% on Insider Selling

GRAIL, Inc. (NASDAQ: GRAL - Get Free Report)'s stock price dropped 5.6% on Friday after an insider sold shares in the company. The stock traded as low as $129.03 and last traded at $127.9350. 67,481 shares traded hands d…

● WSJOct 12, 2026 · 05:30 ET
First-Class Amenity Kits Have Become Holy Grail Collectibles

For a rare breed of travel enthusiast, the free toiletry pouches are more than a throwaway convenience. They're a trip down memory lane.…

● The Motley FoolOct 11, 2026 · 04:11 ET
Grail Stock Hit a 12-Month High After Its FDA Panel Win. But Here's the Risk Investors Shouldn't Ignore.

Grail's stock surged after a positive FDA panel vote. Insurer adoption is crucial for Galleri's success.…

● Defense WorldOct 11, 2026 · 02:59 ETEARNINGS EXPECTED BY FEB 19
Head to Head Contrast: Gilead Sciences (NASDAQ:GILD) vs. GRAIL (NASDAQ:GRAL)

Gilead Sciences (NASDAQ: GILD - Get Free Report) and GRAIL (NASDAQ: GRAL - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their e…

● Fool - Investing NewsOct 8, 2026 · 15:55 ET
2 Growth Stocks to Buy in October

Grail and Veeva Systems could be well insulated from near-term headwinds.…

● 24/7 Wall StreetOct 7, 2026 · 09:35 ET
Why CVS Is ‘Insanely Cheap,' ON Semi a Laggard Catching Up, and Grail Too Expensive to Chase

Jim Cramer sees three stocks with very different amounts of bad news or good news already baked into their prices, and figuring out which side each sits on changes everything about whether to buy.…

● PRNewsWireOct 5, 2026 · 16:01 ETCOMPANY'S OWN WORDS
GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at EDCC and ESMO Congress 2026

GRAIL to Present Six Abstracts at the Early Detection of Cancer Conference (EDCC) Spanning Clinical Performance, Health Equity, and Real-World Implementation of Multi-Cancer Early Detection GRAIL to Present Two Abstracts…

● The Motley FoolOct 4, 2026 · 09:53 ET
Grail Stock Has Skyrocketed 171% in 6 Months. Where Will It Be in 5 Years?

Adoption by insurers and FDA approval are critical for future performance. Profitability is not expected until 2032/2033, but revenue growth could be strong if adoption accelerates.…

● Defense WorldOct 2, 2026 · 06:21 ET
GRAIL (NASDAQ:GRAL) Shares Climb 5.5% – Time to Buy?

Shares of GRAIL, Inc. (NASDAQ: GRAL - Get Free Report) rose 5.5% during mid-day trading on Wednesday. The stock traded as high as $141.97 and last traded at $144.0280. Approximately 113,792 shares were traded during trad…

● Defense WorldOct 1, 2026 · 04:01 ET
GRAIL (NASDAQ:GRAL) Hits New 12-Month High – Should You Buy?

Shares of GRAIL, Inc. (NASDAQ: GRAL - Get Free Report) hit a new 52-week high on Thursday. The company traded as high as $151.46 and last traded at $140.12, with a volume of 1920136 shares trading hands. The stock had pr…

● The Motley FoolSep 30, 2026 · 13:15 ET
3 Reasons to Buy Grail (GRAL) Hand Over Fist in October

Grail's stock recently hit its all-time high. If the FDA approves Galleri, it still looks reasonably valued.…

● PRNewsWireSep 23, 2026 · 18:17 ET
FDA Advisory Committee Votes In Favor of Approval of GRAIL's Galleri® Multi-Cancer Early Detection Test

SUNNYVALE, Calif., Sept. 23, 2026 /PRNewswire/ -- GRAIL, Inc., a healthcare company whose mission is to detect cancer early when it can be cured, today announced a favorable vote from the Molecular and Clinical Genetics …

● PRNewsWireSep 3, 2026 · 16:02 ETCOMPANY'S OWN WORDS
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SUNNYVALE, Calif., Sept. 3, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the for…

● PRNewsWireAug 31, 2026 · 16:01 ETCOMPANY'S OWN WORDS
GRAIL to Present at Morgan Stanley's 24th Annual Global Healthcare Conference

MENLO PARK, Calif., Aug. 31, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the…

Kept in their own lane. A press release is the company talking, not reporting.

Expected by Feb 19. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

Article counts from the last market-wide feed page, across every symbol we track and not just GRAL · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.